In particular, the mRNA expression of VPS26A was significantly related to the levels of KRAS, and TP53 mutations (Figure 2F,G), and correlated with the genetic status (deletion or amplification) of VPS26A in PAAD (Figure 2D). This evidence concerns the gene KRAS and pancreatic adenocarcinoma.